Clinical Trial

Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Name: Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy — clinical trial record (NCT06722950)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A randomized, double-blind, placebo-controlled, multicenter, Phase II clinical study of AC591 in preventing Oxaliplatin-Induced Peripheral Neuropathy

Trial Details

NCT Number	NCT06722950
Lead Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions	Colorectal Adenoma
Enrollment	120 participants
Start Date	2024-12
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-12-09